Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5' RACE.
Camus V, Viennot M, Viailly PJ, Drieux F, Veresezan EL, Bobée V, Rainville V, Bohers E, Sesques P, Haioun C, Durot E, Bayaram M, Rossi C, Martin L, Penther D, Kaltenbach S, Bruneau J, Paillassa J, Tournilhac O, Gower N, Willaume A, Antier C, Renaud L, Leveque E, Decazes P, Becker S, Tonnelet D, Gaulard P, Tilly H, Molina T, Traverse-Glehen A, Donzel M, Ruminy P, Jardin F. Camus V, et al. Among authors: tonnelet d. Blood Adv. 2024 Sep 18:bloodadvances.2024013723. doi: 10.1182/bloodadvances.2024013723. Online ahead of print. Blood Adv. 2024. PMID: 39293080
Dosimetry for targeted radionuclide therapy in routine clinical practice: experts advice vs. clinical evidence.
Dieudonné A, Bailly C, Cachin F, Edet-Sanson A, Kraeber-Bodéré F, Hapdey S, Merlin C, Robin P, Salaun PY, Schwartz P, Tonnelet D, Vera P, Courbon F, Carlier T. Dieudonné A, et al. Among authors: tonnelet d. Eur J Nucl Med Mol Imaging. 2024 Mar;51(4):947-950. doi: 10.1007/s00259-023-06568-8. Eur J Nucl Med Mol Imaging. 2024. PMID: 38110711 Free PMC article. No abstract available.
High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma.
Camus V, Viailly PJ, Drieux F, Veresezan EL, Sesques P, Haioun C, Durot E, Patey M, Rossi C, Martin L, Rainville V, Bohers E, Ruminy P, Penther D, Kaltenbach S, Bruneau J, Paillassa J, Tournilhac O, Willaume A, Antier C, Lazarovici J, Lévêque E, Decazes P, Becker S, Tonnelet D, Berriolo-Riedinger A, Gaulard P, Tilly H, Molina TJ, Traverse-Glehen A, Jardin F. Camus V, et al. Among authors: tonnelet d. Blood Adv. 2023 Dec 12;7(23):7331-7345. doi: 10.1182/bloodadvances.2023011169. Blood Adv. 2023. PMID: 37862676 Free PMC article.
Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study.
Camus V, Rossi C, Sesques P, Lequesne J, Tonnelet D, Haioun C, Durot E, Willaume A, Gauthier M, Moles-Moreau MP, Antier C, Lazarovici J, Monjanel H, Bernard S, Tardy M, Besson C, Lebras L, Choquet S, Le Du K, Bonnet C, Bailly S, Damaj G, Laribi K, Maisonneuve H, Houot R, Chauchet A, Jardin F, Traverse-Glehen A, Decazes P, Becker S, Berriolo-Riedinger A, Tilly H. Camus V, et al. Among authors: tonnelet d. Blood Adv. 2021 Oct 12;5(19):3862-3872. doi: 10.1182/bloodadvances.2021004778. Blood Adv. 2021. PMID: 34461634 Free PMC article.
15 results